MY208922A - Pharmaceutical composition comprising ensifentrine - Google Patents

Pharmaceutical composition comprising ensifentrine

Info

Publication number
MY208922A
MY208922A MYPI2022000719A MYPI2022000719A MY208922A MY 208922 A MY208922 A MY 208922A MY PI2022000719 A MYPI2022000719 A MY PI2022000719A MY PI2022000719 A MYPI2022000719 A MY PI2022000719A MY 208922 A MY208922 A MY 208922A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
dry powder
ensifentrine
powder pharmaceutical
particles
Prior art date
Application number
MYPI2022000719A
Other languages
English (en)
Inventor
Lionel Spargo Peter
James French Edward
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of MY208922A publication Critical patent/MY208922A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2022000719A 2019-08-12 2020-08-12 Pharmaceutical composition comprising ensifentrine MY208922A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1911517.9A GB201911517D0 (en) 2019-08-12 2019-08-12 Pharmaceutical composition
PCT/GB2020/051914 WO2021028679A1 (en) 2019-08-12 2020-08-12 Pharmaeutical composition comprising ensifentrine

Publications (1)

Publication Number Publication Date
MY208922A true MY208922A (en) 2025-06-11

Family

ID=67991071

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022000719A MY208922A (en) 2019-08-12 2020-08-12 Pharmaceutical composition comprising ensifentrine

Country Status (15)

Country Link
US (1) US20220265549A1 (https=)
EP (1) EP4013384A1 (https=)
JP (1) JP7678793B2 (https=)
KR (1) KR20220045214A (https=)
CN (1) CN114286672A (https=)
AU (1) AU2020328223B2 (https=)
BR (1) BR112022002630A2 (https=)
CA (1) CA3144713A1 (https=)
GB (1) GB201911517D0 (https=)
IL (2) IL326396A (https=)
MX (1) MX2022001724A (https=)
MY (1) MY208922A (https=)
PH (1) PH12022550322A1 (https=)
WO (1) WO2021028679A1 (https=)
ZA (1) ZA202201322B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7307855B2 (ja) * 2019-10-11 2023-07-12 テレフオンアクチーボラゲット エルエム エリクソン(パブル) 無線通信ネットワークにおける設定ダウンリンク送信および動的ダウンリンク送信をハンドリングする方法および装置
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN120787157A (zh) * 2022-10-20 2025-10-14 维罗纳制药公司 使用恩塞芬汀治疗特发性肺纤维化
KR20250087621A (ko) * 2022-10-28 2025-06-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
AU2024309346C1 (en) 2023-06-26 2026-03-12 Verona Pharma Plc Particulate composition comprising ensifentrine
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
DE60005493T2 (de) 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
EP2968312B1 (en) * 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
KR20220045214A (ko) 2022-04-12
ZA202201322B (en) 2024-06-26
IL290447A (en) 2022-04-01
CN114286672A (zh) 2022-04-05
BR112022002630A2 (pt) 2022-05-03
WO2021028679A1 (en) 2021-02-18
GB201911517D0 (en) 2019-09-25
WO2021028679A8 (en) 2022-02-24
CA3144713A1 (en) 2021-02-18
AU2020328223B2 (en) 2025-09-04
JP2022550664A (ja) 2022-12-05
US20220265549A1 (en) 2022-08-25
JP7678793B2 (ja) 2025-05-16
IL290447B1 (en) 2026-03-01
IL326396A (en) 2026-04-01
PH12022550322A1 (en) 2023-02-13
MX2022001724A (es) 2022-03-11
EP4013384A1 (en) 2022-06-22
AU2020328223A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MY208922A (en) Pharmaceutical composition comprising ensifentrine
MY123544A (en) New inhalable powder containing tiotropium
MXPA02010212A (es) Composiciones farmaceuticas para inhaladores de polvo seco.
ZA200108688B (en) Powder inhaler for combined medicament.
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
WO2008084312A3 (en) Micronised particles of low-dosage strength active agents for powder formulations for inhalation
NZ515042A (en) Powder inhaler for combined medicament
GB0107106D0 (en) Powder inhaler formulations
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
WO2006008517A3 (en) Use of dry powder compositions for pulmonary delivery
PH12021550767A1 (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
TNSN06277A1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
WO2022240379A3 (en) A stable pharmaceutical composition comprising selexipag
MX2020007745A (es) Administracion de dosis elevadas de terapias inhaladas.
MX2025008306A (es) Polvos secos inhalables
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
CA2499273A1 (en) Inhalation compositions
MY140890A (en) New tiotropium containing powder formulation for inhalation
PL365736A1 (en) Bimodal dry powder formulation for inhalation
ZA202306144B (en) Inhalable powder comprising voriconazole in crystalline form
IL163736A0 (en) Powder formulations suitable for inhalation
CN104800192A (zh) 一种罗氟司特吸入粉雾剂及制备方法
MY191295A (en) Pharmaceutical composition containing budesonide and formoterol
MX2021014343A (es) Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.